Literature DB >> 10726401

[Stroke: prevalence, incidence, trends, East-West comparison. Initial results of the 1998 Federal Health Survey].

G Wiesner1, J Grimm, E Bittner.   

Abstract

The prevalence of survival after a stroke is dependent on the incidence and the fatality rate, whereby the incidence and the fatality rate are influenced by different factors. A survey can only include the minor cases of post-stroke conditions. The prevalence figures thus only reflect the less serious or rehabilitated strokes. Despite this underrepresentation of strokes in the survey we can observe an underestimation of the stroke problem in Germany. Whereas we previously assumed 440,000 to 500,000 strokes in Germany, the projection from the data of the German National Health Interview and Examination Survey amounted to around 945,000 cases (only strokes with "minor" motor, sensory and cognitive losses and restrictions which allow a participation in the survey). The lifetime prevalence rate of the 18-< 80 year old female population is somewhat higher than the male population of the same age (n.s.). The 50 to < 60 year old men have a relatively high prevalence rate. The corresponding age specific prevalence rates increase with increasing age. There are no significant differences in morbidity between the former East and West German states, the prevalence rates of men are somewhat higher in the East and those of women in the West. We can see the following trends in a comparison of the lifetime prevalence rates between 1997/98 and 1990/92: the number of post-stroke conditions among German men 25-< 70 years old declined significantly, among women they increased slightly (n.s.); the prevalence as a whole also declined significantly among men in western Germany, among women they increased slightly (n.s.) in contrast to former West Germany the prevalence rates among men in eastern Germany increased slightly, among women they were almost cut in half. 32.8% of the population with "minor" post-stroke conditions is characterized by sensory disruptions, 32.1% by impairments when walking, 31.3% by paralyses, 20.5% by speech impairments, 17.1% by cognitive disorders and 3.1% by disturbances of consciousness.

Entities:  

Mesh:

Year:  1999        PMID: 10726401

Source DB:  PubMed          Journal:  Gesundheitswesen        ISSN: 0941-3790


  7 in total

1.  Projection of Morbidity 2030 and 2050: Impact for the National Health System and Blood Supply.

Authors:  Alexander Katalinic; Elke Peters; Fritz Beske; Ron Pritzkuleit
Journal:  Transfus Med Hemother       Date:  2010-05-20       Impact factor: 3.747

Review 2.  [Controlled trials on the efficacy of occupational therapy with elderly. Part I: Research question, search strategy and methodological quality of trials].

Authors:  S Voigt-Radloff; T Schochat; H W Heiss
Journal:  Z Gerontol Geriatr       Date:  2004-12       Impact factor: 1.281

Review 3.  [Present status and future possibilities of adjuvant pharmacotherapy for aphasia].

Authors:  C Korsukewitz; C Breitenstein; M Schomacher; S Knecht
Journal:  Nervenarzt       Date:  2006-04       Impact factor: 1.214

Review 4.  [Silent brain infarcts].

Authors:  M A Ritter; R Dittrich; E B Ringelstein
Journal:  Nervenarzt       Date:  2011-08       Impact factor: 1.214

Review 5.  [Thrombophilias in patients with ischemic stroke. Indication and calculated costs for evidence-based diagnostics and treatment].

Authors:  R Weber; E Busch
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

6.  [Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke].

Authors:  Christa Claes; Thomas Mittendorf; Martin Grond; Johann-Matthias Graf von der Schulenburg
Journal:  Med Klin (Munich)       Date:  2009-01-23

7.  The impact of social status inconsistency on cardiovascular risk factors, myocardial infarction and stroke in the EPIC-Heidelberg cohort.

Authors:  Stefanie Braig; Richard Peter; Gabriele Nagel; Silke Hermann; Sabine Rohrmann; Jakob Linseisen
Journal:  BMC Public Health       Date:  2011-02-16       Impact factor: 3.295

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.